



**An die interessierte Partei / To whom it may concern**

**Dr. Stefan Dreiheller**  
Quality Unit / Regulatory Affairs

Date of issue: 10.12.2019  
Page 1/1  
Doc.-No. EIP-0015  
Revision 6

MEGGLE products:

- Lactose Monohydrate Ph. Eur. / USP-NF / JP: CapsuLac® 60, FlowLac® 90, FlowLac® 100, GranuLac® 70, GranuLac® 140, GranuLac® 200, GranuLac® 230, PrismaLac® 40, SacheLac® 80, SorboLac® 400, SpheroLac® 100, Tablettose® 70, Tablettose® 80, Tablettose® 100
- Lactose Monohydrate USP-NF / Ph. Eur. / JP: InhaLac® 70, InhaLac® 120, InhaLac® 140, InhaLac® 150, InhaLac® 160, InhaLac® 230, InhaLac® 250, InhaLac® 251, InhaLac® 400, InhaLac® 500, Lactose monohydrate Low Endotoxin
- Anhydrous Lactose USP-NF / Ph. Eur. / JP: DuraLac® H
- Co-processed excipients: Cellactose® 80, CombiLac®, MicroceLac® 100, RetaLac®, StarLac®

It is the aim of nanotechnology to achieve new material properties which were previously unknown via building up nanostructures in materials.

The products

- are not manufactured using nanotechnology techniques,
- do not contain "engineered nanomaterial" in the meaning of Regulation (EU) No 2015/2283,
- do not contain "substances at nanoscale" in the meaning of French Decree no. 2012-232.

Freundliche Grüße / Best regards

**Molkerei MEGGLE Wasserburg GmbH & Co. KG**

  
Dr. Stefan Dreiheller